Research graph
References from Comparative pharmacokinetic derivations for axicabtagene ciloleucel and brexucabtagene autoleucel in the treatment of B cell malignancies. Local targets link to admitted publications; unresolved targets remain external evidence.
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
10.1056/nejmoa1914347 · 2020 · External reference
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
10.1056/nejmoa1707447 · 2017 · External reference
Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1-2 Trial
10.1016/s1470-2045(18)30864-7 · 2019 · External reference
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
10.1016/s0140-6736(20)31366-0 · 2020 · External reference
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
10.1182/blood.2022018730 · 2023 · External reference
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
10.1056/nejmoa1804980 · 2019 · External reference
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
10.1016/s1470-2045(21)00375-2 · 2021 · External reference
Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients
10.1016/j.jtct.2023.12.672 · 2024 · External reference
Post-infusion CAR T(Reg) cells identify patients resistant to CD19-CAR therapy
10.1038/s41591-022-01960-7 · 2022 · External reference
Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification
10.1021/ac202578x · 2012 · External reference
Single molecule detection in nanofluidic digital array enables accurate measurement of DNA copy number
10.1007/s00216-009-2729-5 · 2009 · External reference
Chimeric antigen receptor T cells for sustained remissions in leukemia
10.1056/nejmoa1407222 · 2014 · External reference
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
10.1172/jci85309 · 2016 · External reference
Application of droplet digital PCR for the detection of vector copy number in clinical CAR/TCR T cell products
10.1186/s12967-020-02358-0 · 2020 · External reference
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
10.1016/s0140-6736(21)01222-8 · 2021 · External reference
Digital PCR Panel for Sensitive Hematopoietic Chimerism Quantification after Allogeneic Stem Cell Transplantation
10.3390/ijms17091515 · 2016 · External reference
Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
10.3389/fonc.2019.00726 · 2019 · External reference
Digital PCR to assess gene-editing frequencies (GEF-dPCR) mediated by designer nucleases
10.1038/nprot.2016.027 · 2016 · External reference
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
2023 · External reference
Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
10.3389/fimmu.2023.1303935 · 2023 · External reference
Lymphodepletion in Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: A Focus on Brain Tumors
10.14791/btrt.2024.0037 · 2024 · External reference
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
10.1182/blood-2018-11-887067 · 2019 · External reference
In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma
10.1002/cpt.2561 · 2022 · External reference
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
10.1056/nejmoa2301665 · 2023 · External reference
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
10.1016/j.ymthe.2016.10.020 · 2017 · External reference
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
10.1182/blood-2011-10-384388 · 2012 · External reference
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
10.1172/jci126397 · 2019 · External reference
Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel
10.1016/j.omtm.2019.12.018 · 2020 · External reference
Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR
10.3390/cancers12071970 · 2020 · External reference
Pois(s)on--it's a question of dose
10.1038/sj.gt.3302270 · 2004 · External reference
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity
10.1182/bloodadvances.2024012637 · 2024 · External reference
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
10.1182/bloodadvances.2018029678 · 2019 · External reference
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
10.1200/jco.2018.77.8084 · 2018 · External reference
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management
10.1002/ajh.26151 · 2021 · External reference
Adoptive cell transfer as personalized immunotherapy for human cancer
10.1126/science.aaa4967 · 2015 · External reference
A safe and potent anti-CD19 CAR T cell therapy
10.1038/s41591-019-0421-7 · 2019 · External reference
Quantitative PCR methodology with a volume-based unit for the sophisticated cellular kinetic evaluation of chimeric antigen receptor T cells
10.1038/s41598-020-74927-8 · 2020 · External reference
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
10.1182/blood-2017-06-786129 · 2017 · External reference
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
10.1016/s0140-6736(14)61403-3 · 2015 · External reference
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity
10.1182/bloodadvances.2024012637 · 2024 · External reference
Corrigendum to 'Rapid degradation of the organophosphate pesticide - Chlorpyrifos by a novel strain of pseudomonas nitroreducens AR-3', [Bioresource Technology 292 (2019) 122025]
10.1016/j.biortech.2020.124093 · 2020 · External reference
Bioanalytical Assay Strategies and Considerations for Measuring Cellular Kinetics
10.3390/ijms24010695 · 2022 · External reference
Flow Cytometry for Estimating Plant Genome Size: Revisiting Assumptions, Sources of Variation, Reference Standards, and Best Practices
10.21273/jashs05376-24 · 2024 · External reference
The complete sequence of a human genome
10.1126/science.abj6987 · 2022 · External reference
Re-calibration of flow cytometry standards for plant genome size estimation
10.3389/fpls.2025.1548766 · 2025 · External reference
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
10.1182/blood-2013-08-519413 · 2013 · External reference
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
10.1200/jco.2014.56.2025 · 2015 · External reference
